胰高血糖素样肽-1受体激动剂使用与麻醉前胃残余内容物
这项横断面研究于2023年6月6日至7月12日在一所大学附属医院前瞻性纳入124例遵循术前禁食指南的择期麻醉患者,用胃超声评估胃残余内容物增加。GLP-1 RA使用者的胃残余内容物增加患病率为56%(35/62),对照组为19%(12/62);校正混杂后GLP-1 RA使用与胃残余内容物增加患病率升高30.5%(95%CI 9.9%-51.2%)相关(校正患病率比2.48,95%CI 1.23-4.97)。停药时长与胃残余内容物增加无关联(校正OR 0.86,95%CI 0.65-1.14)。
要点
- GLP-1 RA使用者麻醉前胃超声示胃残余内容物增加患病率56%,对照组19%。
- 校正混杂后GLP-1 RA使用与胃残余内容物增加患病率升高30.5%相关。
- GLP-1 RA停药时长与胃残余内容物增加患病率无关联(校正OR 0.86,95%CI 0.65-1.14)。
核心结论
- GLP-1 RA使用与麻醉前胃超声所见的胃残余内容物增加独立相关。
- 研究结果提示现行指南建议的术前禁食时长在该类误吸风险增加的患者中可能不足。
研究设计与样本
- 横断面研究,前瞻性纳入2023年6月6日至7月12日一所大型三级大学附属医院在麻醉下接受择期操作的患者。
- 共纳入124例参与者,中位年龄56岁(IQR 46-65岁),女性75例(60%)。
- 暴露为每周一次GLP-1 RA使用;采用增强逆概率治疗加权(基于倾向评分的方法)校正混杂。
- 排除胃解剖改变(如既往胃手术)、妊娠、近期创伤(<1个月)或无法取右侧卧位行胃超声者。
主要发现
- 胃残余内容物增加(胃超声见固体、稠液体或清液体超过1.5 mL/kg)患病率:GLP-1 RA使用组56%(35/62) vs 未使用GLP-1 RA对照组19%(12/62)。
- 校正混杂后,GLP-1 RA使用与胃残余内容物增加患病率升高30.5%(95%CI 9.9%-51.2%)相关(校正患病率比2.48,95%CI 1.23-4.97)。
- GLP-1 RA停药时长与胃残余内容物增加患病率无关联(校正OR 0.86,95%CI 0.65-1.14)。
关键数值与推荐
- 胃残余内容物增加定义为胃超声见固体、稠液体或清液体超过1.5 mL/kg。
- 主要结局为胃残余内容物增加的存在;次要探索GLP-1 RA停药时长与胃残余内容物增加患病率的关联。
临床怎么用
- 原文结论指出,现行指南建议的术前禁食时长在GLP-1 RA使用这一误吸风险增加的患者群体中可能不足。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is rapidly increasing in the US, driven by its expanded approval for weight management in addition to hyperglycemia management in patients with type 2 diabetes. The perioperative safety of these medications, particularly with aspiration risk under anesthesia, is uncertain. OBJECTIVE: To assess the association between GLP-1 RA use and prevalence of increased residual gastric content (RGC), a major risk factor for aspiration under anesthesia, using gastric ultrasonography. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study prospectively enrolled patients from a large, tertiary, university-affiliated hospital from June 6 through July 12, 2023. Participants followed preprocedural fasting guidelines before an elective procedure under anesthesia. Patients with altered gastric anatomy (eg, from previous gastric surgery), pregnancy, recent trauma (<1 month), or an inability to lie in the right lateral decubitus position for gastric ultrasonography were excluded. EXPOSURE: Use of a once-weekly GLP-1 RA. MAIN OUTCOMES AND MEASURES: The primary outcome was the presence of increased RGC, defined by the presence of solids, thick liquids, or more than 1.5 mL/kg of clear liquids on gastric ultrasonography. Analysis was adjusted for confounders using augmented inverse probability of treatment weighting, a propensity score-based technique. Secondarily, the association between the duration of drug interruption and the prevalence of increased RGC was explored. RESULTS: Among the 124 participants (median age, 56 years [IQR, 46-65 years]; 75 [60%] female), the prevalence of increased RGC was 56% (35 of 62) in patients with GLP-1 RA use (exposure group) compared with 19% (12 of 62) in patients who were not taking a GLP-1 RA drug (control group). After adjustment for confounding, GLP-1 RA use was associated with a 30.5% (95% CI, 9.9%-51.2%) higher prevalence of increased RGC (adjusted prevalence ratio, 2.48; 95% CI, 1.23-4.97). There was no association between the duration of GLP-1 RA interruption and the prevalence of increased RGC (adjusted odds ratio, 0.86; 95% CI, 0.65-1.14). CONCLUSIONS AND RELEVANCE: Use of a GLP-1 RA was independently associated with increased RGC on preprocedural gastric ultrasonography. The findings suggest that the preprocedural fasting duration suggested by current guidelines may be inadequate in this group of patients at increased risk of aspiration under anesthesia.
引用
- Sen S, Potnuru PP, Hernandez N, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surg. 2024. PMID: 38446466. doi:10.1001/jamasurg.2024.0111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。